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Importance—Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is 
causally associated with the risk of coronary heart disease (CHD), but randomized trials of several 
therapies that reduce Lp(a) levels by 25% to 35% have not provided any evidence that lowering 
Lp(a) level reduces CHD risk.
Objective—To estimate the magnitude of the change in plasma Lp(a) levels needed to have the 
same evidence of an association with CHD risk as a 38.67-mg/dL (ie, 1-mmol/L) change in low-
density lipoprotein cholesterol (LDL-C) level, a change that has been shown to produce a 
clinically meaningful reduction in the risk of CHD.
Design, Setting, and Participants—A mendelian randomization analysis was conducted 
using individual participant data from 5 studies and with external validation using summarized 
data from 48 studies. Population-based prospective cohort and case-control studies featured 20 793 
individuals with CHD and 27 540 controls with individual participant data, whereas summarized 
data included 62 240 patients with CHD and 127 299 controls. Data were analyzed from 
November 2016 to March 2018.
Exposures—Genetic LPA score and plasma Lp(a) mass concentration.
Main Outcomes and Measures—Coronary heart disease.
Results—Of the included study participants, 53% were men, all were of white European 
ancestry, and the mean age was 57.5 years. The association of genetically predicted Lp(a) with 
CHD risk was linearly proportional to the absolute change in Lp(a) concentration. A 10-mg/dL 
lower genetically predicted Lp(a) concentration was associated with a 5.8% lower CHD risk (odds 
ratio [OR], 0.942; 95% CI, 0.933-0.951; P = 3 × 10−37), whereas a 10-mg/dL lower genetically 
predicted LDL-C level estimated using an LDL-C genetic score was associated with a 14.5% 
lower CHD risk (OR, 0.855; 95% CI, 0.818-0.893; P = 2 × 10−12). Thus, a 101.5-mg/dL change 
(95% CI, 71.0-137.0) in Lp(a) concentration had the same association with CHD risk as a 38.67-
mg/dL change in LDL-C level. The association of genetically predicted Lp(a) concentration with 
CHD risk appeared to be independent of changes in LDL-C level owing to genetic variants that 
mimic the relationship of statins, PCSK9 inhibitors, and ezetimibe with CHD risk.
Conclusions and Relevance—The clinical benefit of lowering Lp(a) is likely to be 
proportional to the absolute reduction in Lp(a) concentration. Large absolute reductions in Lp(a) 
of approximately 100 mg/dL may be required to produce a clinically meaningful reduction in the 
risk of CHD similar in magnitude to what can be achieved by lowering LDL-C level by 38.67 
mg/dL (ie, 1 mmol/L).
Apolipoprotein(a), which is encoded by the LPA gene, co-valently binds to a cholesterol-
rich low-density lipo-protein (LDL) particle to form lipoprotein(a) (Lp[a]).1 Meta-analyses 
of prospective observational studies have reported that higher plasma Lp(a) concentration is 
associated with dose-dependent higher risk of coronary heart disease (CHD).2 Furthermore, 
mendelian randomization analyses have provided strong evidence that the association 
between Lp(a) and risk of CHD is likely to be causal.3–5 However, several large randomized 
trials evaluating therapies that lower Lp(a) concentration by between 20% and 35% 
(including niacin, cholesterol ester transfer protein inhibitors, and PCSK9 inhibitors) have 
not provided clear evidence that lowering plasma Lp(a) concentration reduces the risk of 
cardiovascular events beyond that which would be expected from the observed LDL-
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lowering effect of these therapies.6–11 Although these trials were not specifically designed 
to assess the Lp(a)-lowering effect of these agents, these trials raise the question of how 
much Lp(a) concentration must be lowered to produce a clinically meaningful reduction in 
cardiovascular events. Therapies that more specifically and potently lower Lp(a) 
concentrations by up to 90% by inhibiting apolipoprotein(a) synthesis are in development.12 
Whether lowering Lp(a) concentrations with these new therapies will reduce the risk of 
cardiovascular events is unknown.
Owing to the skewed distribution of plasma Lp(a) concentration, prior studies have reported 
the association between log-transformed concentrations of Lp(a) and CHD risk.2,13–15 
Changes in log-transformed Lp(a) concentrations represent proportional changes in Lp(a) 
concentrations. However, proportional reduction is not a useful metric for assessing the 
potential clinical benefit of lowering Lp(a) level because concentrations can vary by as much 
as 1000-fold among members of the same population, and therefore, the same proportional 
change in Lp(a) concentration can result in markedly different absolute changes, depending 
on the initial Lp(a) concentration.16
Importantly, statins and other therapies that reduce LDL particle concentrations are 
associated with a dose-dependent reduction in the risk of cardiovascular events that is 
determined by the absolute (rather than the proportional) change in LDL cholesterol (LDL-
C) level.17–19 Because Lp(a) contains an LDL particle, we hypothesized that there would 
be evidence to support a clinical association of Lp(a) with the risk of CHD that may also be 
proportional to the absolute change in circulating Lp(a) mass concentration. To test this 
hypothesis, we created a genetic score to estimate the magnitude and shape of the 
relationship of Lp(a) with the risk of CHD. We then estimated the absolute change in plasma 
Lp(a) concentration required to achieve the equivalent change in CHD risk as a 38.67-mg/dL 
(ie, 1-mmol/L) change in LDL-C level (to convert to millimoles per liter, multiply by 
0.0259), a change in LDL-C that has been demonstrated to produce a clinically meaningful 
20% to 25% reduction in the risk of cardiovascular events in short-term trials.17–19 Our 
objective was to make inferences about how much Lp(a) concentration must be reduced 
pharmacologically to produce a clinically meaningful reduction in CHD risk and thereby 
determine who is most likely to benefit from treatment with Lp(a)-lowering therapy to 
inform clinical guidelines and the design of randomized trials evaluating Lp(a)-lowering 
therapies.
Methods
Study Population and Outcomes
We studied 48 333 participants of European descent (including 20 793 with CHD) from 5 
studies for whom individual participant–level data were available as part of the CHD Exome
+ Consortium. Descriptions of the included studies are provided in eMethods 1 of the 
Supplement. The primary outcome was CHD, defined as CHD death, nonfatal myocardial 
infarction, or (for 3 of the studies) other coronary events with International Statistical 
Classification of Diseases and Related Health Problems, Tenth Revision codes I20-25. 
Participants provided written informed consent for genetic studies. As this was an analysis 
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of anonymized data that had already been collected, ethical approval was not sought for this 
particular investigation.
LPA Genetic Score
All CHD Exome+ Consortium participants were genotyped using a customized version of 
the Illumina Exome Beadchip array, which included ultrafine mapping of the LPA gene 
region involving 2426 variants genotyped within a 660-kb window (eFigure 1 in the 
Supplement). To select variants for inclusion in the genetic score, we identified variants in 
the LPA gene region that were conditionally associated with Lp(a) concentrations at a 
genome-wide level of significance (P < 5 × 10−8) using forward stepwise regression among 
participants free from CHD at baseline in each study. We adjusted for study, age, sex, and 5 
principal components of ancestry. Genetic variants correlated with a selected variant at r2 
greater than 0.4 were excluded from further steps of the procedure (eFigure 2 in the 
Supplement). For each participant, we calculated a weighted genetic score by summing the 
number of Lp(a)-raising alleles inherited at each variant included in the score, weighted by 
each variant’s association with absolute change in Lp(a) mass concentration (measured in 
milligrams per deciliter). In sensitivity analyses, we repeated the primary analyses using 
different choices of variants in the genetic scores, as described in eMethods 2 in the 
Supplement.
Study Design
To assess the dose-response shape of the association between genetically predicted Lp(a) 
and CHD risk, we divided participants into deciles of the genetic score and measured the 
association between each decile of genetically predicted Lp(a) concentration and the risk of 
CHD using the first decile as the reference group. Informed by the shape of the association, 
we estimated the association between the LPA score and the risk of CHD for absolute 
changes in Lp(a) concentration.
To estimate the absolute reduction in Lp(a) concentration required to have the same change 
in CHD risk as a 38.67-mg/dL decrease in LDL-C level, we used the following protocol 
(eFigure 3 in the Supplement). First, we measured the association between the LPA score 
and the risk of CHD per 10-mg/dL decrease in genetically predicted Lp(a) concentration. 
Next, we measured the association between a genetic score consisting of variants in or near 
genes that encode the targets of currently available LDL-C–lowering therapies and CHD risk 
per 10-mg/dL decrease in genetically predicted LDL-C (eTable 1 in the Supplement).20 We 
then calculated the ratio between these 2 estimates to obtain the change in Lp(a) 
concentration that has an equivalent association with CHD risk as a 1-mg/dL change in 
LDL-C level. To estimate the amount Lp(a) concentration must be reduced to have the same 
association with CHD risk as a 38.67-mg/dL reduction in LDL-C level, we multiplied this 
ratio by 38.67. Finally, we estimated the predicted short-term change associated with 
different magnitudes of pharma-cological lowering of Lp(a) concentration by converting the 
change in Lp(a) concentration into a change in LDL-C level having an equivalent predicted 
effect on CHD risk and using the estimated change associated with statin treatment per 
38.67-mg/dL reduction in LDL-C level, as reported by the Cholesterol Treatment Trialists’ 
Collaboration.17
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Statistical Analyses
We estimated the association of each variant with Lp(a) or LDL-C concentration using linear 
regression and with CHD risk using logistic regression. All regression analyses were 
performed separately in each of the studies, adjusting for age, sex, and the first 5 principal 
components of ancestry; these estimates were combined across studies in a fixed-effects 
inverse variance-weighted meta-analysis. Heterogeneity was assessed using the I2 statistic. 
Mendelian randomization estimates were then obtained from these variant-specific estimates 
using a previously reported method that accounts for correlation between variants.21 
Nonlinearity in the mendelian randomization estimates of the shape of the association of 
Lp(a) change with the risk of CHD was assessed using fractional polynomials, as described 
elsewhere.22 For external replication in an independent sample, we performed the same 
analyses using summarized genetic associations with CHD risk from the Coronary Artery 
Disease Genome Wide Replication and Meta-analysis (CARDIOGRAM) plus The Coronary 
Artery Disease (C4D) Genetics (CARDIOGRAMplusC4D) consortium in up to 62 240 
patients and 127 299 controls.23
All analyses were performed using the statistical software platform R version 3.4.1 (R 
Programming). A detailed description of the methods is provided in eMethods 2 of the 
Supplement.
Results
Participant Characteristics
The baseline characteristics of participants are presented in Table 1. Across the 5 studies 
contributing to the initial sample, the median Lp(a) concentration varied from 13.6 mg/dL to 
43.3 mg/dL (eTable 2 and eFigure 4 in the Supplement).
LPA Genetic Score
The stepwise selection procedure identified 43 genetic variants conditionally associated with 
Lp(a) (eTable 3 in the Supplement). The genetic score comprising these variants explained 
51% to 63% of the variance in Lp(a) concentration in each study (eFigure 5 in the 
Supplement). This explanatory ability is lower than observed previously24 because our 
genetic score was constructed conservatively to minimize bias owing to overfitting. 
Associations of each variant with Lp(a) concentration and CHD risk are displayed in Figure 
1.
Association of LPA Genetic Score With CHD
In analyses dividing the population into deciles of genetically predicted absolute Lp(a) mass 
concentration, the exposure–outcome association for log-transformed CHD risk was 
approximately linear, ie, fixed changes in absolute Lp(a) concentrations led to equal odds 
ratios (ORs) for CHD regardless of the starting Lp(a) concentration (Figure 2A). By 
contrast, the exposure–outcome association for deciles of log-transformed Lp(a) 
concentration was curvilinear (Figure 2B), with fixed proportional changes in Lp(a) 
concentrations leading to greater log-ORs for individuals with higher baseline Lp(a) 
concentrations (and hence, increasingly greater absolute changes in Lp[a] concentrations). 
Burgess et al. Page 5
JAMA Cardiol. Author manuscript; available in PMC 2019 April 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
These findings are consistent and support the hypothesis that the risk of CHD is log-linearly 
proportional to absolute changes in Lp(a) concentration.
Overall, each 10-mg/dL lower genetically predicted Lp(a) level was associated with a 5.8% 
lower risk of CHD (OR, 0.942; 95% CI, 0.933-0.951; P = 3 × 10−37). There was no evidence 
of heterogeneity with similar genetic association estimates obtained across all studies 
independent of the type of Lp(a) assay used (eFigures 6 and 7 in the Supplement). Estimates 
were also similar in sensitivity analyses that varied the number of genetic variants included 
in the LPA score (eTable 4 in the Supplement). In external replication analyses involving 
participants from CARDIOGRAMplusC4D, a 10-mg/dL lower genetically predicted Lp(a) 
level was associated with a 5.2% lower risk of CHD (OR, 0.948; 95% CI, 0.941-0.955; P = 1 
× 10−47).
Expected Clinical Benefit of Lowering Lp(a) Concentration
Using the LDL-C genetic score, a 10-mg/dL genetically predicted lower LDL-C level was 
associated with a 14.5% lower risk of CHD (OR, 0.855; 95% CI, 0.818-0.893; P = 2 × 
10−12) (eFigure 8 in the Supplement). This finding suggests that a 1-mg/dL difference in 
LDL-C level has the same association with CHD risk as a 2.63-mg/dL difference in Lp(a) 
concentration (ie, log[0.855] / log[0.942] = 2.63), and therefore, a 38.67-mg/dL difference in 
LDL-C level has the same association as a 101.5-mg/dL (95% CI, 71.0-137.0) difference in 
Lp(a) concentration. In external replication analyses using data from 
CARDIOGRAMplusC4D, a 10-mg/dL lower LDL-C level was associated with a 14.0% 
lower CHD risk (OR, 0.860; 95% CI, 0.841-0.879; P = 3 × 10−40), suggesting that a 109.1-
mg/dL (95% CI, 89.0-133.1) difference in Lp(a) concentration has the same association with 
CHD risk as a 38.67-mg/dL difference in LDL-C level.
Changes in genetically predicted Lp(a) and LDL-C concentrations represent lifelong 
exposure to these lipoproteins. Hence, to estimate the effect of lowering Lp(a) concentration 
in a short-term trial, we assumed that if lifelong exposure to 101.5-mg/dL lower Lp(a) 
concentration has the same association with CHD risk as lifelong exposure to 38.67-mg/dL 
lower LDL-C level, then short-term exposure to 101.5-mg/dL lower Lp(a) concentration 
should have the same association with CHD risk as short-term exposure to 38.67-mg/dL 
lower LDL-C levels observed in randomized trials. This assumption is valid only if changes 
in Lp(a) concentration and LDL-C level have similar cumulative associations with CHD 
over time. It is further supported by the observation that the ratio of the association of 
lifelong exposure to Lp(a) with CHD risk estimated from mendelian randomization to the 
association of intermediate-term exposure to Lp(a), estimated from observational studies in 
the Emerging Risk Factors Consortium,2 is very similar to the ratio of the association of 
lifelong exposure to LDL-C with CHD risk estimated from mendelian randomization to the 
association of intermediate-term exposure to LDL-C in the Emerging Risk Factors 
Consortium (Figure 3; eFigure 9 in the Supplement).25 Therefore, Lp(a) and LDL-C appear 
to have similar cumulative associations with the risk of CHD over time.
Table 2 shows the expected clinical benefit in CHD risk from both lifelong and short-term 
exposure to absolute differences in Lp(a) concentration. Lifelong estimates are conventional 
mendelian randomization estimates, while short-term estimates are calculated using the 
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difference in Lp(a) concentration needed to achieve the same change for a given reduction in 
LDL-C level over a median of 5 years of treatment with a statin, as reported by the 
Cholesterol Treatment Trialists’ Collaboration.18
Independent Association of Lp(a) and LDL-C–Lowering Therapies
To assess whether the association of lowering Lp(a) concentration with the risk of CHD is 
likely to be independent of lowering LDL-C level with statins, we divided the population 
into 3 groups based on the number of LDL-C–lowering alleles each participant inherited at a 
common variant (rs12916) in the 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) 
gene, which encodes the target of statins.26,27 The LPA score had nearly identical 
associations per 10-mg/dL lower Lp(a) concentration in each of these 3 groups (CC 
genotype group: OR, 0.945; 95% CI, 0.927-0.964; CT genotype group: OR, 0.939; 95% CI, 
0.927-0.952; TT genotype group: OR, 0.945; 95% CI, 0.932-0.957; P = .79 for difference) 
(eFigure 10 in the Supplement), suggesting that the relative risk reduction of lowering Lp(a) 
concentration is likely to be independent of lowering LDL-C level with statins. Similar 
findings were observed for genetic variants in the PCSK9 and NPC1L1 gene regions that 
mimic the changes associated with PCSK9 inhibitors and ezetimibe, respectively.
Discussion
We found that the association of genetically predicted plasma Lp(a) with the risk of CHD 
was linearly proportional to the absolute difference in Lp(a) concentration. Absolute 
differences in Lp(a) concentration of approximately 100 mg/dL had an equivalent 
association with CHD risk as a 38.67-mg/dL difference in LDL-C level. The results of this 
study may have important implications for informing clinical practice guidelines on the use 
of Lp(a)-lowering therapies, for designing randomized trials to evaluate Lp(a)-lowering 
therapies currently in development, and for designing screening programs to reduce the 
global burden of CHD.
Because a 100-mg/dL difference in Lp(a) concentration had the same association with CHD 
risk as a 38.67-mg/dL difference in LDL-C level, the results of this study suggest that 
pharmacologically lowering Lp(a) concentration by approximately 100 mg/dL should reduce 
the risk of CHD (CHD death or nonfatal myocardial infarction) by approximately 22% to 
25% in a 3- to 5-year randomized trial, similar to the association that has been observed for a 
38.67-mg/dL reduction in LDL-C level during treatment with a statin.17–19 Therefore, it 
follows that lowering Lp(a) concentration by 80 mg/dL might be expected to reduce the risk 
of CHD events by approximately 18% to 20%, while lowering Lp(a) concentration by 50 
mg/dL might reduce CHD events by 10% to 12% (Table 2), assuming that there are no 
unrecognized competing risks associated with lowering Lp(a) concentration. Therefore, only 
persons with very high Lp(a) concentrations are likely to benefit substantially from therapies 
that reduce Lp(a) concentration.
This finding likely explains why therapies that reduce Lp(a) concentration by 20% to 35% 
have failed to provide clear evidence that lowering Lp(a) concentration reduces the risk of 
cardiovascular events in previous randomized trials even though Lp(a) is a genetically 
supported target. The median Lp(a) concentration among participants enrolled in these trials 
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was approximately 12 to 20 mg/dL.7–11 Therefore, a 30% reduction in Lp(a) concentration 
would translate into only a 3- to 6-mg/dL absolute reduction in circulating plasma Lp(a) 
concentration, a small absolute reduction that was likely far too modest to reduce the risk of 
cardiovascular events appreciably in a short-term randomized trial.
The results of this study suggest that randomized trials evaluating new, more potent Lp(a)-
lowering therapies in development should be designed to enroll individuals with very high 
baseline Lp(a) concentrations of 90 to 100 mg/dL or more. Reducing Lp(a) concentration by 
80% to 90% in such individuals should translate into large absolute reductions in Lp(a) 
concentrations of 70 to 90 mg/dL, which should in turn translate into approximately a 15% 
to 20% proportional reduction in the risk of CHD events. Enrolling patients at high risk of 
CHD owing to markedly elevated Lp(a) concentration in the initial proof-of-concept clinical 
trials is similar to the strategy used by the Scandinavian Simvastatin Survival Study trial,28 
which enrolled high-risk patients with markedly elevated LDL-C concentrations and was the 
first trial to demonstrate that treatment with statins led to large, clinically meaningful 
reductions in the risk of cardiovascular events.
The magnitude of the pharmacologic reduction in Lp(a) mass that is likely needed to 
produce clinically meaningful reductions in CHD risk estimated in this study is larger than 
estimated in a 2018 study evaluating changes in Lp(a) during treatment with niacin.29 
However, whereas that previous study involved informal estimates of the reversible CHD 
risk by lowering Lp(a) concentrations in a short-term trial,29 we used a more systematic 
approach. In particular, our study estimated the differences in genetically predicted Lp(a) 
and LDL-C concentrations needed to have the same change in lifetime CHD risk and 
incorporated an assessment of the differential cumulative associations of Lp(a) and LDL-C 
with CHD risk over time to estimate how much Lp(a) concentration must be lowered 
pharmacologically to produce the same change as lowering LDL-C level by 38.67 mg/dL 
(ie, 1 mmol/L) with a statin. This approach has been successfully used to accurately 
anticipate the results of several recent trials.26,27,30 Similar analyses to those used in the 
current study are needed before it would be possible to accurately anticipate the potential 
effect of pharmacologically lowering Lp(a) on the risk of stroke, peripheral vascular disease, 
aortic stenosis, or composite end points that include these outcomes.31
Finally, it should be noted that plasma Lp(a) concentration is largely heritable. Therefore, if 
the linear relationship with CHD risk continues at very high absolute Lp(a) concentrations 
(as occurs for LDL-C), then Lp(a) concentrations in excess of 200 mg/dL may be associated 
with a 3- to 4-fold increased lifetime risk of CHD (OR, 3.30; 95% CI, 2.75-3.96) and thus 
may represent an inherited lipoprotein disorder that is associated with a similar lifetime risk 
of CHD as heterozygous familial hypercholesterolemia but with a prevalence that may be 2-
fold higher than that of heterozygous familial hypercholesterolemia.32,33 Therefore, 
screening for individuals with extremely elevated Lp(a) concentrations and treating them 
with one of the new Lp(a)-lowering therapies in development could potentially have the 
same effect on reducing the global burden of CHD as current screening programs designed 
to detect and treat individuals with familial hypercholesterolemia.
Burgess et al. Page 8
JAMA Cardiol. Author manuscript; available in PMC 2019 April 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Limitations
Our study has limitations. Multiple different assays were used to measure Lp(a) 
concentrations in the included studies. However, we focused only on absolute differences in 
Lp(a) associated with genetic variants, which were very similar across all included studies, 
regardless of assay used or baseline Lp(a) concentrations. In addition, our estimate of the 
effect of lowering Lp(a) is agnostic to the mechanism of action, and hence our use of plasma 
Lp(a) mass concentration to estimate the dose-response relationship does not imply that our 
estimates are solely via changes in plasma Lp(a) mass concentration. If pharmacologic Lp(a) 
lowering has associations not adequately captured by the genetic variants (eg, antithrombotic 
associations), then smaller absolute reductions in Lp(a) than estimated here may produce 
clinically meaningful reductions in CHD risk.34
Conclusions
The association of genetically predicted Lp(a) with CHD risk was linearly proportional to 
the absolute change in Lp(a) mass concentration. Large absolute reductions in Lp(a) 
concentration of approximately100mg/dLare likely necessary to achieve clinically 
meaningful reductions in the risk of CHD similar in magnitude to what can be achieved by 
lowering LDL-C level by 38.67mg/dL (ie, 1 mmol/L) with a statin.
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Key Points
Question How much does plasma lipoprotein(a) need to be lowered to produce a 
clinically meaningful reduction in the risk of coronary heart disease?
Findings In a mendelian randomization analysis involving more than 80 000 patients and 
more than 150 000 controls, coronary heart disease risk was proportionally associated 
with the absolute change in plasma lipoprotein(a) mass concentration; a 101.5-mg/dL 
change in lipoprotein(a) concentration was associated with the same coronary heart 
disease risk as a 38.67-mg/dL (ie, 1-mmol/L) change in low-density lipoprotein 
cholesterol level.
Meaning Lipoprotein(a) concentration must be lowered by approximately 100 mg/dL to 
achieve the same reduction in coronary heart disease risk as can be achieved by lowering 
low-density lipoprotein cholesterol level by 38.67 mg/dL.
Burgess et al. Page 14
JAMA Cardiol. Author manuscript; available in PMC 2019 April 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1. Association of LPA Variants With Lipoprotein(a) (Lp[a]) Concentration and Coronary 
Heart Disease (CHD) Risk
Marginal genetic associations with Lp(a) and CHD risk (error bars indicate 95% confidence 
intervals) obtained in the CHD Exome+ consortium for 43 variants included in the LPA 
genetic score. Associations are orientated to the minor allele.
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Figure 2. Shape of Association Between Genetically Predicted Lipoprotein(a) (Lp[a]) and 
Coronary Heart Disease (CHD) Risk
A, Arithmetic mean of Lp(a) in each decile (untransformed, linear scale).
B, Geometric mean of Lp(a) in each decile (log-transformed, log-scale). Points on the curve 
indicate mendelian randomization estimates in each decile of genetically predicted Lp(a) 
(error bars indicate 95% confidence intervals; first decile is reference group). The solid line 
indicates the best-fitting fractional polynomial (left, linear term only; right, square root and 
cubic terms) to model the dose-dependent relationship; the dotted lines indicate the 95% 
confidence intervals for the relationship.
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Figure 3. Estimates of Coronary Heart Disease (CHD) Risk Reduction With Lowering of Low-
Density Lipoprotein Cholesterol (LDL-C) Level and Lipoprotein(a) (Lp[a]) Concentration
Genetic estimates of lifelong lowering from mendelian randomization (brown line), 
observational estimates from prospective cohort studies (blue line), and (A) trial estimate 
from short-term statin trials (for LDL-C) or (B) predicted trial estimate (for Lp[a]) (orange 
line). The vertical line is at 38.67 mg/dL (ie, 1 mmol/L) for LDL-C level and at 101.5 mg/dL 
for Lp(a) concentration, the estimated equivalent lowering in Lp(a) for the same reduction in 
CHD risk. To convert LDL-C to millimoles per liter, multiply by 0.0259.
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Table 1
Baseline Characteristics of Participants
Source No
Patients With CHD 
No Lp(a) Measured No.a Age, Mean (SD), y Men, No
Lp(a) Concentration, mg/dL
Mean (SD) Median
CCHS 7808 1943    7396 58 (15) 3463 29.3 (33.6) 16.9
CGPS-CIHDS 17 120 7740    9964 59 (13) 9635 25.0 (28.1) 13.6
EPIC-CVD 20 780 9810 15 899 55 (10) 9792 52.6 (37.1) 43.3
PROSPER 1279   641         0 76 (4)   708 NA NA
WOSCOPS 1346   659    1017 56 (6) 1346 36.0 (39.3) 19.0
Abbreviations: CCHS, Copenhagen City Heart study; CGPS, Copenhagen General Population study; CHD, coronary heart disease; CIHDS, 
Copenhagen Ischemic Heart Disease study; EPIC-CVD, European Prospective Investigation Into Cancer and Nutrition-Cardiovascular Disease 
study; Lp(a), lipoprotein (a); PROSPER, Prospective Study of Pravastatin in the Elderly at Risk study; WOSCOPS, West of Scotland Coronary 
Prevention study.
aValues of Lp(a) concentration were winsorized at 130 mg/dL.
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Table 2
Expected Clinical Benefit of Lowering Lp(a)
Reduction in Lp(a) 
Concentration, mg/dL
Reduction in LDL-C Level for 
Equivalent CHD Risk Reduction, 
mg/dL (95% CI)a
Estimated Lifelong Proportional 
Risk Reduction Owing to 
Genetically Decreased Exposure, 
% (95% CI)b
Estimated Short-term 
Proportional Risk Reduction in 
Randomized Trial, % (95% 
CI)c
120 45.7 (34.1-65.4) 51.1 (45.5-56.2) 27.7 (20.9-37.5)
100 38.1 (28.4-54.5) 44.9 (39.7-49.8) 23.7 (17.8-32.4)
  80 30.5 (22.7-43.6) 38.0 (33.2-42.3) 19.4 (14.5-26.9)
  50 19.0 (14.2-27.3) 25.8 (22.3-29.1) 12.6 (9.3-17.8)
  30 11.4 (8.5-16.4) 16.4 (14.1-18.7)   7.8 (5.7-11.1)
  20   7.6 (5.7-10.9) 11.3 (9.6-12.9)   5.3 (3.8-7.5)
  10   3.8 (2.8-5.5)   5.8 (4.9-6.7)   2.7 (1.9-3.9)
    5   1.9 (1.4-2.7)   2.9 (2.5-3.4)   1.3 (1.0-1.9)
Abbreviations: CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a).
SI conversion factor: To convert LDL-C to millimoles per liter, multiply by 0.0259.
a
Each mg/dL lower Lp(a) has an association with CHD risk that is equivalent to a 0.38-mg/dL reduction in LDL-C based on the ratio of the 
associations of the genetic scores with CHD risk.
b
Effect size (95% confidence interval) for Lp(a) reduction obtained from mendelian randomization approach.
c
Effect size (95% confidence interval) for Lp(a) reduction obtained by considering equivalent lowering of LDL-C and in comparison with estimate 
from randomized trials of statins on major coronary events (risk ratio, 0.76; 95% CI, 0.73-0.78).
JAMA Cardiol. Author manuscript; available in PMC 2019 April 24.
